Indonesia is expanding its immunization strategy to combat a persistent measles crisis, with the National Agency of Drug and Food Control (BPOM) officially extending the use of measles vaccines to high-risk adult populations. The move, announced during a press conference on April 8, 2026, is a strategic response to ongoing outbreaks that have strained public health resources across 14 provinces.
The decision to expand the vaccine’s indication comes as the government grapples with an Extraordinary Occurrence (KLB) of measles. While child immunization remains the primary focus of national health programs, health authorities have observed a critical gap in adult immunity, leaving a significant portion of the workforce and vulnerable populations exposed to the highly contagious virus.
According to data from the Ministry of Health, the scale of the 2026 outbreak has been extensive. By the 11th week of the year, 58 KLB events were recorded across 39 regencies and cities. Although the government reported a significant 93% decline in cases—dropping from a peak of 2,220 cases to 146 by mid-March 2026—officials warn that the risk of transmission remains high, particularly among adults with suboptimal immunization coverage.
BPOM Head Taruna Ikrar emphasized that the policy is a direct response to a public health emergency. “The people suffering from measles are not just children, but there are likewise cases in adult groups,” Ikrar stated, noting that the agency moved quickly to ensure that safe, effective and high-quality vaccines are accessible to those most at risk.
A Data-Driven Shift in Vaccination Policy
The expansion of the vaccine’s use was not an abrupt decision but the result of a comprehensive scientific evaluation. As a WHO-Listed Authority (WLA) for vaccines, BPOM adhered to international standards of rigor, consulting with the World Health Organization and the National Drug Assessment Committee.
The evaluation process involved a deep dive into clinical trial data and real-world evidence to ensure that the expanded indication for adults met strict safety and efficacy standards. This scientific vetting culminated in the official approval on April 7, 2026, for the use of Bio Farma’s measles vaccine in high-risk adults.
By approving the domestically produced Bio Farma vaccine for adults, BPOM is not only addressing a health gap but also optimizing the use of national pharmaceutical resources. Previously, these doses were prioritized for children; the new policy allows the government to leverage existing domestic supply to protect the adult population without relying solely on imports.
Comparing Available Adult Vaccine Options
While the Bio Farma vaccine is now a primary tool for the national response, it joins a suite of other available options for adults. The following table outlines the current landscape of measles protection for the adult population in Indonesia.
| Vaccine Type | Manufacturer | Primary Focus/Availability |
|---|---|---|
| Measles Vaccine | Bio Farma | Domestic production; now expanded for high-risk adults |
| MMR (Measles, Mumps, Rubella) | GlaxoSmithKline (GSK) | Combination vaccine; available for adult groups |
| MMR (Measles, Mumps, Rubella) | Merck Sharp & Dohme (MSD) | Combination vaccine; available for adult groups |
Prioritizing the Frontlines: Who is Eligible?
The government is not implementing a universal adult vaccination campaign but is instead focusing on “high-risk populations” to maximize the impact of the current vaccine stockpile. This targeted approach ensures that those most likely to contract or spread the virus are protected first.
Priority groups for the expanded vaccination include:
- Healthcare Workers: As the first line of defense, medical staff are prioritized to prevent them from becoming vectors of transmission within clinical settings.
- International Travelers: Individuals moving between borders are at higher risk of introducing new strains or contracting the virus in regions with different epidemiological profiles.
- Close Contacts of Immunocompromised Patients: Because individuals with weakened immune systems cannot always be vaccinated or are highly susceptible, protecting the adults around them creates a “cocoon” of safety.
Sukamto Koesnoe, Chair of the Adult Immunization Task Force of the Indonesian Society of Internal Medicine (PAPDI), noted that this is not a new medical recommendation, but rather a formalization of existing clinical advice. He clarified that recommendations for adult vaccination in risk groups have existed long before the current outbreak, making the BPOM approval a critical step in making those recommendations actionable on a national scale.
Logistics and National Stockpile Management
A primary concern during any outbreak response is the “cold chain” and the actual availability of doses. Lucia Rizka Andalusia, Director General of Pharmacy and Medical Devices at the Ministry of Health, confirmed that the infrastructure is in place to support the rollout.
As of the announcement, Indonesia maintains a national stock of approximately 9.8 million measles vaccine doses. This supply provides a buffer of roughly 5.5 months, allowing the Ministry of Health to execute the vaccination program in stages, following the established priority list.
The coordination between BPOM, the Ministry of Health, and professional medical organizations is intended to create a seamless pipeline from regulatory approval to the patient’s arm. By integrating domestic production with a targeted distribution strategy, the government aims to suppress the current KLB and prevent future spikes in 2026 and beyond.
Disclaimer: This article is provided for informational purposes only and does not constitute medical advice. Please consult a healthcare provider or official government health portals for personal vaccination guidance.
The next phase of the program will involve the gradual distribution of the 9.8 million doses to regional health centers, with the Ministry of Health expected to provide updated surveillance data on the 14 affected provinces to determine if the priority list needs further adjustment.
We invite readers to share their thoughts on the national immunization strategy in the comments below or share this report with colleagues in the healthcare sector.
